Loading...
Header Logo
Keywords
Last Name
Institution

Connection

Peter Friedmann to Narcotic Antagonists

This is a "connection" page, showing publications Peter Friedmann has written about Narcotic Antagonists.

 
Connection Strength
 
 
 
3.340
 
  1. Park TW, Friedmann PD. Medications for addiction treatment: an opportunity for prescribing clinicians to facilitate remission from alcohol and opioid use disorders. R I Med J (2013). 2014 Oct 01; 97(10):20-4.
    View in: PubMed
    Score: 0.606
  2. Andrews CM, D'Aunno TA, Pollack HA, Friedmann PD. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med Care Res Rev. 2014 Feb; 71(1):43-60.
    View in: PubMed
    Score: 0.564
  3. D'Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations. Health Serv Res. 2014 Feb; 49(1):230-48.
    View in: PubMed
    Score: 0.557
  4. Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, Flynn PM, Welsh WN, Stein LA, Sacks S, O'Connell DJ, Knudsen HK, Shafer MS, Hall E, Frisman LK. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012; 33(1):9-18.
    View in: PubMed
    Score: 0.501
  5. Allen AA, Chen DT, Bonnie RJ, Ko TM, Suratt CE, Lee JD, Friedmann PD, Gordon M, McDonald R, Murphy SM, Boney TY, Nunes EV, O'Brien CP. Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. J Subst Abuse Treat. 2017 Oct; 81:66-72.
    View in: PubMed
    Score: 0.184
  6. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016 Mar 31; 374(13):1232-42.
    View in: PubMed
    Score: 0.168
  7. Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015 Mar; 41:110-7.
    View in: PubMed
    Score: 0.155
  8. Friedmann PD, Mello D, Lonergan S, Bourgault C, O'Toole TP. Aversion to injection limits acceptability of extended-release naltrexone among homeless, alcohol-dependent patients. Subst Abus. 2013; 34(2):94-6.
    View in: PubMed
    Score: 0.134
  9. Friedmann PD, Schwartz RP. Just call it "treatment". Addict Sci Clin Pract. 2012; 7:10.
    View in: PubMed
    Score: 0.129
  10. Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O'Brien CP. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012; 33(1):48-59.
    View in: PubMed
    Score: 0.125
  11. Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, Anderson BJ. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010 Sep; 39(2):157-66.
    View in: PubMed
    Score: 0.113
  12. Friedmann PD, Jiang L, Alexander JA. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. J Behav Health Serv Res. 2010 Jul; 37(3):322-37.
    View in: PubMed
    Score: 0.103
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.